Fractyl Health, Inc. (NASDAQ:GUTS) CEO Harith Rajagopalan Sells 90,972 Shares of Stock

Fractyl Health, Inc. (NASDAQ:GUTS) CEO Harith Rajagopalan sold 90,972 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $1.82, for a total value of $165,569.04. Following the completion of the sale, the chief executive officer now owns 491,329 shares of the company’s stock, valued at approximately $894,218.78. This represents a 15.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Harith Rajagopalan also recently made the following trade(s):

• On Monday, November 11th, Harith Rajagopalan sold 96,517 shares of Fractyl Health stock. The shares were sold at an average price of $2.47, for a total transaction of $238,396.99.

Fractyl Health Price Performance

Fractyl Health stock opened at $1.70 on Tuesday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.57 and a current ratio of 5.58. The business has a fifty day moving average of $2.06 and a two-hundred day moving average of $2.51. Fractyl Health, Inc. has a one year low of $1.68 and a one year high of $13.99. The company has a market cap of $81.77 million and a P/E ratio of -0.14.

Fractyl Health (NASDAQ:GUTS) last posted its earnings results on Tuesday, November 12th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.02. The firm had revenue of $0.01 million during the quarter. As a group, analysts predict that Fractyl Health, Inc. will post -1.66 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley cut their price target on Fractyl Health from $18.00 to $10.00 and set an “overweight” rating for the company in a research note on Monday.

Institutional Investors Weigh In On Fractyl Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets lifted its holdings in Fractyl Health by 54.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock valued at $53,000 after purchasing an additional 7,397 shares in the last quarter. Jane Street Group LLC acquired a new stake in Fractyl Health during the third quarter worth about $25,000. Rhumbline Advisers raised its holdings in Fractyl Health by 73.1% in the fourth quarter. Rhumbline Advisers now owns 25,626 shares of the company’s stock valued at $53,000 after buying an additional 10,826 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Fractyl Health by 335.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 14,807 shares of the company’s stock valued at $37,000 after acquiring an additional 11,406 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Fractyl Health during the third quarter worth about $33,000.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.